On June 29, 2015, the U.S. Supreme Court ruled that the Environmental Protection Agency 23 (EPA) acted unreasonably when it determined that cost was irrelevant to deciding whether it was 24 "appropriate" to regulate emissions of Hazardous Air Pollutants (HAPs) from coal and oil-fired 25 utilities (EGUs) (U.S. Supreme Court, Michigan v. EPA, 2015) . According to the 1990 Clean Air 26 Act Amendments, EPA must make a preliminary determination, known as the "appropriate and 27 necessary" finding, before regulating EGUs. The Court ruled that EPA made a mistake at this 28 preliminary stage and sent the regulation, known as the Mercury and Air Toxics Standards 29 (MATS), back to the agency and ordered EPA to consider costs. The public comment period for 30 this proposal closed on January 15, 2016 and EPA aims to issue a final cost consideration and 31 renewed "appropriate and necessary" finding by April 15, 2016. 32
33
In its 2011 regulatory assessment 1 , EPA concluded that the monetized benefits for all air 34 pollutants (both direct benefits and co-benefits) associated with MATS range between $37 and 35 $90 billion and far exceed the costs of regulation. However, most of these quantified benefits 36 come from reductions in particulate emissions. Monetized benefits associated with reducing 37 HAP emissions in EPA's regulatory assessment ranged between $4-$6 million, leading some 38 critics to argue that the rule was unreasonable. However, both the scientific community and EPA 39 have repeatedly emphasized the many additional, significant, unquantified benefits of this 40 regulation that further outweigh the costs. Even preliminary efforts to monetize these benefits 41 suggest they are substantially greater than the costs of the proposed regulation. 42
43
Although EGUs release a variety of HAPs, we will focus specifically on the benefits associated 44 with reducing emissions of mercury and exposures to its organic form, methylmercury, which is 45 scientific literature, we find the monetized benefits for EGU mercury emissions reductions identified by EPA in the regulatory impact analysis supporting MATS vastly understate the 48 benefits associated with reductions of those emissions. 49
Specifically we elaborate upon three key points below: 50 1. Recent research demonstrates that quantified societal benefits associated with declines in 51 mercury deposition attributable to implementation of MATS are much larger than the 52 amount estimated by EPA in 2011. 53
2.
As-yet-unquantified benefits to human health and wildlife from reductions in EGU 54 mercury emissions are substantial. 55
3. Contributions of EGUs to locally deposited mercury have been underestimated by EPA's 56 regulatory assessments. 57
Quantified societal benefits associated with declines in mercury deposition attributable 58
to implementation of MATS are much larger than the amount estimated by the EPA in 59
1 60
Due to data limitations and gaps in the available research, EPA's regulatory assessment only 61 considered a small subset of the public health and environmental risks associated with mercury 62 emissions from EGUs. Specifically, EPA monetized the value of IQ losses for children born to a 63 limited population of recreational fishers who consume freshwater fish during pregnancy from 64 watersheds where EPA had fish tissue data. The monetized value of benefits for this small If one considers instead all of the benefits of reducing EGU mercury emissions, recent research 67 confirms that the benefits are orders of magnitude greater than those quantified by EPA in 2011. 68
One study found that the cumulative U.S. economy-wide benefits associated with 69 implementation of MATS exceeded $43 billion. 2 This value is far greater than EPA's estimate of 70 the costs associated with the regulation. Other work has estimated an annual benefit of $860 71 million associated with a 10% reduction in methylmercury exposure in the U.S. population. 3 72 2. As-yet unquantified benefits to human health and wildlife are substantial. 73
In part these estimates are so much greater than the quantified benefits identified in EPA's 74 regulatory assessment because they consider additional types of benefits from reducing EGU 75 mercury emissions. For example, many of these benefits are associated with adverse impacts of 76 methylmercury on cardiovascular health. EPA did not quantify cardiovascular effects in the 77 regulatory assessment. At that time, there was a split in the scientific evidence regarding the 78 significance of those impacts. On one side, an independent expert panel in 2011 asserted there is 79 sufficient scientific evidence to incorporate these outcomes in regulatory assessments. 4 On the 80 other, a high-profile study of risks of cardiovascular disease associated with methylmercury 81 exposures in two U.S. cohorts found no evidence of adverse effects. 5 82
There are several reasons, however, to conclude that the cardiovascular impacts are substantial 83 despite the latter study. First, the study included only low-to-moderate fish consumers and 84 therefore lacked the statistical power to detect effects seen in studies that included a greater 85 range in exposures (e.g., 6 ). Second, it is challenging to isolate the neurodevelopmental and 86 cardiovascular impacts of methylmercury exposure from seafood consumption because seafood serve to mask those deleterious impacts. 7, 8 These confounding effects make it difficult for some 89 epidemiological studies to identify the negative health outcomes associated with methylmercury 90 exposures against the background of beneficial effects of consuming long-chained fatty acids in 91 seafood. However, this does not imply that exposures to methylmercury on its own are not 92 harmful, or that it does not reduce the benefits of an otherwise healthy food source. 9, 10 In 93 addition, imprecision in exposure biomarkers biases many epidemiological studies toward a null 94 finding rather than detection of adverse effects. 11 We note that failure to find a statistically 95 significant effect is not evidence that no such effect exists, though it may provide evidence that 96 constrains the magnitude of the effect. 97
Although EPA's regulatory assessment did quantify one type of neurological effect (IQ loss) 98 among one group of fish consumers, its consideration of neurodevelopmental benefits from the 99 proposed rule is incomplete. For example, the assessment did not consider benefits associated 100 with reductions in methylmercury in coastal U.S. fisheries. It therefore significantly 101 underestimates the neurodevelopmental benefits of the rule, because marine fish account for 102 >90% of methylmercury intake by the U.S. population. 12 These benefits are difficult to quantify 103 because they require attributing changes in methylmercury exposure from domestic, 104 international, and natural sources of mercury. Nevertheless, many species of marine fish eaten by 105 Benefits of MATS associated with declines in mercury deposition to U.S. ecosystems in the 142 regulatory assessment were based on atmospheric modeling that suggested global (non-U.S.) 143 anthropogenic sources would be most important for regional declines in deposition. However, for 144 the past two decades, mercury researchers have noted slow and steady declines in atmospheric 145 mercury concentrations in North America, Europe, and over the open oceans. Initial attempts to 146 rationalize these observations from a scientific perspective were confounded by a commonly 147 held (but incorrect) assumption among researchers that global mercury emission trends from 148 anthropogenic sources were steady or increasing over this same time period. Zhang et al. 23 149 recently corrected an error in previous emissions inventories on the form of mercury released by 150
EGUs over time. This correction helps enable global models to reproduce the observed declining 151 atmospheric mercury trends and shows that local and regional mercury deposition to U.S. 152 ecosystems is much more influenced by domestic actions than previously assumed. 
